Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., according to CEO Thomas Schinecker, who declined to reveal what these assets are.

Roche said on Tuesday it would invest $50 billion in the United States over the next five years, creating more than 12,000 new jobs, in the latest massive investment by companies reacting to President Donald Trump's tariff policy.

The pharma giant said the investment would create more than 12,000 jobs, as it joins rival Novartis in expanding its footprint in the country amid President Trump’s tariff threats.